The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

Meta: In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic ...

The two were close friends, with their friendship going back about two decades. Read more at straitstimes.com. Read more at ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

As new research spotlights the obesity-cancer connection, experts warn we’ve underestimated just how much excess weight – and the complex biology behind it – can fuel the disease.

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

Canine and human cancers bear many similarities — studies in dogs are helping to develop treatments for both species.

Whilst some factors are out of our control, there are easy lifestyle choices we can all make to protect our health ...